8-K: Moleculin Biotech Regains Nasdaq Listing Compliance

Moleculin Biotech, Inc. announced it has regained compliance with Nasdaq's minimum stockholders' equity requirement, leading to the cancellation of its delisting hearing.

Summary

• Moleculin Biotech, Inc. (the "Company") previously received a letter on May 23, 2025, from Nasdaq's Listing Qualifications Department, indicating non-compliance with Listing Rule 5550(b)(1) due to not maintaining a minimum of $2.5 million in stockholders' equity.
• The Company also did not meet the alternative requirements of market value of listed securities or net income from continuing operations.
• On November 20, 2025, the Company received a delist determination letter from Nasdaq staff, prompting the Company to request a hearing panel appeal.
• As of January 6, 2026, Nasdaq staff informed the Panel that the Company had regained compliance with Listing Rule 5550(b)(1) and is now in compliance with all applicable continued listing standards.
• Consequently, the hearing before the Panel has been cancelled.

Sentiment

Score: 8

Explanation: The sentiment is highly positive as the company successfully resolved a critical regulatory issue that threatened its public listing, removing a major overhang and stabilizing its market position.

Positives

• The Company has successfully regained compliance with Nasdaq's Listing Rule 5550(b)(1), which requires a minimum of $2.5 million in stockholders' equity.
• The delisting determination hearing before the Nasdaq Panel has been cancelled, removing the immediate threat of the Company's common stock being delisted.
• The Company is now in compliance with all applicable continued listing standards of The Nasdaq Stock Market LLC.

Negatives

• The Company was previously non-compliant with Nasdaq's Listing Rule 5550(b)(1) for not maintaining a minimum of $2.5 million in stockholders' equity.
• The Company received a delist determination letter on November 20, 2025, indicating a significant risk to its public listing status.

Risks

• The previously identified risk of delisting from The Nasdaq Stock Market LLC due to non-compliance with Listing Rule 5550(b)(1) has been mitigated by the Company regaining compliance.

Future Outlook

The filing does not provide specific forward-looking statements or guidance beyond the resolution of the Nasdaq listing compliance issue.

Management Comments

• Jonathan P. Foster, Chief Financial Officer, duly signed the report on behalf of Moleculin Biotech, Inc., indicating management's official communication of the regained compliance.

Industry Context

Maintaining listing compliance is fundamental for publicly traded biotechnology companies like Moleculin Biotech, as it ensures access to capital markets and investor liquidity. Non-compliance can severely impact investor confidence and the ability to fund research and development. Regaining compliance is a critical step in stabilizing the company's market position.

Legal Proceedings

• The Company was involved in a regulatory process with The Nasdaq Stock Market LLC regarding non-compliance with listing rules, which included a delist determination and a requested hearing panel appeal. This process has now concluded with the Company regaining compliance.

Stakeholder Impact

• Shareholders: Positive impact as the threat of delisting is removed, preserving liquidity and market access for their investment.
• Employees: Positive impact as the company's stability and access to capital markets are maintained, potentially securing employment.
• Creditors: Positive impact as the company remains publicly traded, which can be favorable for its financial standing and ability to meet obligations.

Key Dates

Recommendation

The company successfully resolved its Nasdaq listing non-compliance, removing the immediate threat of delisting and maintaining its access to public capital markets. This is a positive development that stabilizes the stock by removing a significant regulatory overhang. However, this filing does not provide new information on fundamental business performance or future prospects to warrant a change in investment thesis beyond holding, pending further operational updates.

Keywords

Moleculin Biotech, MBRX, Nasdaq, Listing Compliance, Stockholders' Equity, Delisting, Biotech